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Abstract
Background: Esophageal squamous cell carcinomas (ESCC) have poor prognosis. While combined modality of
chemotherapy and radiotherapy increases survival, most patients die within five years. Development of agents that confer
cancer cell-specific chemo- and radiosensitivity may improve the therapy of ESCC. We here reported the discovery of
berberine as a potent radiosensitizing agent on ESCC cells.
Principal Findings: Berberine at low concentrations (,15 mM) substantially radiosensitized ESCC cells. X-ray induced DNA
double-strand breaks (DSBs) persist longer in ESCC cells pretreated with berberine. Berberine pretreatment led to a
significant downregulation of RAD51, a key player in homologous recombination repair, in ESCC cells, but not in non-
malignant human cells. Downregulation of RAD51 by RNA interference similarly radiosensitized the cancer cells, and,
conversely, introduction of exogenous RAD51 was able to significantly counteract the radiosensitizing effect of berberine,
thus establishing RAD51 as a key determinant in radiation sensitivity. We also observed that RAD51 was commonly
overexpressed in human ESCC tissues, suggesting that it is necessary to downregulate RAD51 to achieve high radio- or
chemotherapeutic efficacy of ESCC in clinic, because overexpression of RAD51 is known to confer radio- and
chemoresistance.
Conclusions/Significance: Berberine can effectively downregulate RAD51 in conferring radiosensitivity on esophageal
cancer cells. Its clinical application as an adjuvant in chemotherapy and radiotherapy of esophageal cancers should be
explored.
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Introduction
Esophageal squamous cell carcinomas (ESCC), which have a
particularly high incidence in East Asian countries, usually have
poor prognosis. Only a 4% 5-year survival rate was recorded
with surgical care [1]. Radiotherapy had a similar outcome [2].
The survival rate of patients with ESCC can be significantly
improved with combined chemotherapy and radiation therapy
[3,4]. However, increasing the radiation dose does not yield
more satisfactory results [5]. There remains the necessity to
develop agents that confer chemo- and radiosensitivity
selectively on cancer cells while having minimal radiation
toxicity to normal cells. Although various radiation sensitizers
have been tested, including agents that target DNA or non-
DNA targets, the ideal radiation sensitizer remains to be
discovered [6].
Berberine, the main alkaloid component in Huang Lian and
other medicinal herbs, is the most commonly used medicine for
gastrointestinal discomfort in China. Beside its common use as a
daily medicine, a number of laboratory studies have shown that
berberine has antitumor activity for a wide variety of cancer cells,
including glioblastoma [7], oral cancer [8], hepatoma [9], gastric
cancer [10], prostate cancer [11], leukemia [12] and osteosarcoma
[13]. In most cases, berberine was found to inhibit cell cycle
progression and to induce apoptosis. A recent study showed that
berberine was able to suppress the constitutive activation of NF-kB
in some cancer cells [14], where it was found to directly inhibit IkB
kinase (IKK) activation, leading to the suppression of phosphor-
ylation and nuclear translocation of p65. Berberine was also
reported to have a radiosensitizing effect on lung cancer cells by
inducing autophagy [15]. In addition, berberine may impair
tumor growth by inhibiting angiogenesis [16].
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proliferation by inducing DNA double-strand breaks (DSBs).
Berberine, which emits a yellowish fluorescence, was found to be
more intensively accumulated in the nuclei of osteosarcoma cells
than in those of normal osteoblasts, and this differential
accumulation of berberine correlates to its growth-inhibitory
effect, to the induction of DNA damage, and subsequently to the
activation of p53 and cell cycle arrest [13]. Therefore, the signal
transduction pathway underlying the antitumor effect of berberine
is probably similar to those initiated by other DNA-damaging
agents such as cisplatin. A recent report showed that berberine can
up-regulate p53 by disrupting the MDM2-DAXX-HAUSP
interactions and promoting MDM2 self-ubiquitination and
degradation [17].
We here report that berberine at low concentrations can
significantly radiosensitize ESCC cells. We demonstrated that the
radiosensitizing effect of berberine is mediated by the downreg-
ulation of RAD51, which encodes a critical protein in homologous
recombination repair. In addition, we observed that RAD51 was
commonly over-expressed in human ESCC tissues, indicating that
it is necessary to downregulate RAD51 to achieve high radio- or
chemotherapeutic efficacy of ESCC in clinic, because overexpres-
sion of RAD51 is known to confer radio- and chemoresistance.
Results
Berberine sensitizes esophageal cancer cells to ionizing
radiation
As previously reported for other types of cancer cells, berberine
treatment alone had a growth-inhibitory effect on esophageal
cancer cells in a dose- and time-dependent manner (Fig. 1A).
When compared to human normal fibroblasts (HNF), ESCC cells
are more sensitive to berberine. At 72 h, the IC50 for ESCC cells
KYSE450 (12.58 mM), was about a quarter of that for HNF
(51.28 mM) (Fig. 1B). At low concentrations (,15 mM), berberine
had a relatively low toxicity to ESCC cells and induced no
detectable apoptosis (Fig. 1C). However, ESCC cells that were
pretreated with low concentrations of berberine exhibited a
significantly increased sensitivity to ionizing radiation, as reflected
by the remarkable decrease in their ability to form colonies (Fig. 2).
Berberine pretreatment (15 mM, 24 h) reduced the SF2 (surviving
fraction at 2 Gy) of KYSE30 cells to 48.160.6%, from
77.261.2% in cells that were not pretreated with berberine. A
second ESCC line KYSE450 showed a similar response, with the
SF2 reduced to 50.262.1% when cells were pretreated with
berberine at 15 mM for 48 h, compared to 81.262.6% for cells
not pretreated with berberine. In contrast, berberine had no
radiosensitizing effect on human normal fibroblasts (Fig. 2).
Berberine pretreatment prolongs the persistence of
radiation-induced DSBs
Ionizing radiation kills cells by inflicting various types of damage
to the genome. We speculated that the radiosensitizing effect of
berberine on cancer cells may be caused by impairment in the
repair of DNA double-strand breaks (DSBs). We therefore
determined the levels of DSBs by immunofluoresence staining of
c-H2AX foci in ESCCs at different time points after exposure to
X-rays. As shown in Fig. 3A, in KYSE30 cells not pretreated with
berberine, majority of the c-H2AX foci were cleared at 12 h after
exposure to 0.5 Gy of X-rays, and the average number of c-H2AX
foci subsided to near basal level at 24 h. In contrast, more c-
H2AX foci persisted at those two time points in KYSE30 cells that
were pretreated with berberine (15 mM). The average number of
c-H2AX foci per cell in cells receiving the combined berberine/
radiation treatment was significantly greater compared with the
radiation-only group at 12 and 24 h time points (Fig. 3B)
(P=0.002, and P,0.001, respectively). Berberine treatment alone
was not observed to induce obvious DNA damage in terms of c-
H2AX foci induction over untreated controls (P=0.081).
KYSE450 cells also showed a delayed clearance of the X-ray-
induced c-H2AX foci when they were pretreated with berberine.
While the majority of c-H2AX foci were cleared in control cells at
24 h after exposure to X-rays, more than half of the c-H2AX foci
persisted in cells that were pretreated with berberine (Fig. 3C).
These results indicate that berberine pretreatment impaired the
repair of x-ray-induced DSBs.
Berberine downregulates RAD51 in cancer cells but not
in nonmalignant cells
DSBs are primarily repaired by two pathways, i.e., non-
homologous end joining and homologous recombination
[18,19,20]. Ku70 and Ku86 are essential for the former, where
as RAD51 is a central player in the latter. We next determined
whether the levels of those three proteins were changed in
esophageal cancer cells pretreated with berberine. We observed
that while there were no obvious changes in the levels of Ku70
and Ku86, the level of RAD51 protein was remarkably decreased
in ESCCs that were treated with berberine for 24 h or 48 h at
7.5 mMo r1 5mM (Fig. 4A). The level of RAD51 mRNA showed a
significant reduction in both cancer cell lines after treatment with
berberine (Fig. 4B), suggesting that the downregulation of
RAD51 was probably due to decreased transcription of RAD51
mRNA.
The expression of RAD51 is known to be cell cycle-dependent
and is higher at S and G2/M phases than at G0/G1 phase
[21,22]. To determine whether the reduced expression of RAD51
was due to change in cell cycle distribution in berberine-treated
cells, we subjected berberine-treated cells to flow cytometry
analysis. While berberine treatment (15 mM for 24 h) reduced
the percentage of KYSE30 cells at S and G2/M to 49% from 60%
in control (data not shown), such a change was not enough to
account for the many fold reduction in the level of RAD51
expression. More importantly, berberine treatment (15 mM for
24 h) did not significantly alter the distribution of cell cycle
distribution of KYSE450 cells (44% and 45% for the percentage of
cells at S-G2/M phases in control and treated group, respectively),
indicating that the reduction of RAD51 expression in response to
berberine is not due to reduced population size of cells at S and
G2/M phases. Thus, the downregulation of RAD51 in response to
berberine is probably independent of the expression changes that
are associated with cell cycle progression.
Overexpression of RAD51 is frequently associated with an
increase in its promoter activity [23]. We next cloned the
promoter and the 59end region of RAD51 (from 21693 to
+487 bp) into a luciferase reporter plasmid, pGL3-basic vector,
transfected them into esophageal cancer cells, and tested the
RAD51 promoter activity in response to berberine treatment. As
shown in Fig. 4C, the promoter activity of RAD51 was significantly
reduced in cells that were treated with berberine when compared
to control. Together, these results showed that berberine was able
to downregulate the expression of RAD51 in esophageal cancer
cells at transcription level.
Because RAD51 is a key player in homologous recombination
repair, its downregulation could contribute to the radiosensitivity
of ESCC cells pretreated with berberine. Since berberine had no
radiosensitizing effect on HNF, we speculated that the RAD51
level might not be affected by berberine treatment in HNF. We
first surveyed the basal levels of RAD51 in several nonmalignant
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RAD51 were much lower in HNF, hMSC (human mesenchymal
stem cells derived from umbilical cord) and XWXL (fibroblasts
derived from a benign fibroadenoma) than those in ESCC cells.
Interestingly, human umbilical vascular endothelial cells (HU-
VECs) and HEK-293 cells also expressed high levels of RAD51.
However, in contrast to ESCC cells, none of the four types of
nonmalignant cells showed a downregulation in RAD51 expres-
sion upon berberine treatment (Fig. 4D).
To determine whether the downregulation of RAD51 by
berberine applies to other types of cancer cells, we also exposed
human breast cancer cells MCF7, human osteosarcoma cells
U2OS, mouse prostate cancer cells RM-1 and mouse lung cancer
cells LLC to low concentrations of berberine for 48 h and
measured the protein level of RAD51. As shown in Fig. 4E,
RAD51 was downregulated in all those four cancer cell lines
tested, suggesting that downregulation of RAD51 by berberine is
not unique to ESCC cells. Together, these results indicate that
Figure 1. Growth-inhibitory effect of berberine on esophageal cancer cells. (A), Effect of berberine on the viability of KYSE30, KYSE450 and
HNF cells. Cell viability was assessed by MTT assay. Cells were treated with DMSO or the indicated concentrations of berberine for 24 h, 48 h and
72 h. Results were represented as mean 6 SD from three independent experiments. (B), Cytotoxicity of berberine against KYSE30, KYSE450 and HNF
cells represented by inhibitory concentrations IC50. (C), Measurement of apoptosis by Western blot analysis of caspase-3. KYSE30 and KYSE450 cells
were treated with berberine for 24 h and 48 h, respectively. Paclitaxel-treated HL-60 and HeLa cells as positive control.
doi:10.1371/journal.pone.0023427.g001
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treatment in terms of regulation of RAD51 expression.
Upregulation of RAD51 by IR can be attenuated by
berberine
We observed that ionizing radiation induced an up-
regulation of RAD51 in ESCC cells (Fig. 5A). In consistent
with the increase of RAD51 at protein level, the level of RAD51
mRNA was increased in ESCC cells that had been exposed to
IR (data not shown). This finding is in accordance with a
previous report of RAD51 induction by IR in glioma cells [24].
Because IR can upregulate the expression of RAD51,w en e x t
tested whether berberine pretreatment could counteract this
effect of IR. The ESCC cells were first treated with berberine,
then with IR and the level of RAD51 expression was measured.
In contrast to the elevation of RAD51 in cells that were treated
with IR alone, berberine pretreatment effectively attenuated
the up-regulation of RAD51 induced by IR (Fig. 5B), indicating
that berberine was able to overcome the upregulation of
RAD51 induced by IR. Not only was there a reduction in total
protein level, the formation of RAD51 foci in response to IR
was greatly inhibited by berberine (Fig. 5C). The downregu-
lation of RAD51 by berberine was again reflected at
transcription level (Fig. 5D).
Figure 2. Radiosensitization of esophageal cancer cells by berberine. (A), Radiosensitization by berberine by clonogenic cell survival assay.
KYSE30 and KYSE450 cells were exposed to berberine (15 mM) or vehicle control (DMSO) for 24 and 48 h, respectively, before they were irradiated and
plated. Human normal fibroblast cells were treated with berberine for 24 h and 48 h before they were exposed to X-rays. Data points are the
averages of two independent experiments each plated in triplicate; bars, SE. (B), SF2 values following treatment with berberine. Decrease in the SF2
values indicates the radiosensitizing effects of berberine.
doi:10.1371/journal.pone.0023427.g002
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Because berberine may affect many cellular pathways that are
involved in cell proliferation and survival, it cannot be ruled out
that pathways other than the downregulation of RAD51 were
responsible for the radiosensitizing effect of berbeirne. To
demonstrate that it is the downregulation of RAD51 that is
responsible for this effect of berberine, we next depleted RAD51 in
esophageal cancer cells by RNAi and tested their radiosensitivity.
As shown in Fig. 6A, RAD51 expression could be efficiently
silenced by siRNA specifically targeting RAD51 in both cell lines.
In addition, the spontaneous formation of RAD51 foci was greatly
reduced (Fig. 6B). As expected, the depletion of RAD51 led to a
significant reduction in the clonogenic cell survival for both
esophageal cancer cell lines (Fig. 6C). The SF2 was reduced to
33.360.4% in RAD51-RNAi KYSE30 cells from 78.461.2% in
control. KYSE450 cells showed a similar response to RAD51
depletion. Thus, the radiosensitizing effect of berberine on
esophageal cells was primarily mediated by the downregulation
of RAD51.
Introduction of Exogenous RAD51 counteracts the
radiosensitizing effect of berberine
To further validate the role of RAD51 as a key player in
mediating the radiosensitizing effect of berberine, we made a
construct that expresses murine RAD51 under the CMV
Figure 3. Berberine pre-treatment led to a prolonged persistence of IR-induced c-H2AX foci. (A), Immunofluorescence staining of c-H2AX
in KYSE30 cells. (B), Summary of c-H2AX foci in KYSE30 cells at different time points following various treatments. (C), Summary of c-H2AX foci in
KYSE450 cells at different time points following various treatments. Columns, means of three independent experiments. Cells growing on coverslips
in 6-well plates were exposed to berberine (15 mM) for 24, irradiated (0.5 Gy), and fixed at the specified time points for immunofluorescence analysis.
doi:10.1371/journal.pone.0023427.g003
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transfected. Expression of the exogenous RAD51 was evident in
cells transfected withmRAD51, as shown by Western blot (Fig. 6D).
Importantly,theradiosensitizingeffectofberberinewassignificantly
attenuated in both KYSE30 and KYSE450 cell lines that were
transfected with mRAD51 (Fig. 6E). These results, together with
those obtained with RAD51-RNAi, demonstrated that RAD51 is a
critical determinant of radioresistance in ESCC cells.
RAD51 overexpression is common in esophageal cancer
tissues
Upregulation of RAD51 expression is common in tumor cell
lines [25] and in a number of human malignancies [26,27,28]. We
next evaluated the RAD51 expression level in a panel of 86 human
primary esophageal squamous cell carcinoma tissues by immuno-
histochemical staining. Nuclear and/or cytoplasmic staining of
RAD51 was detected in 81 of 86 specimens. In specimens
exhibiting positive staining of RAD51, subcellular distribution and
intensity were varied. Intensity was scored as 1 in 29, 2 in 43, and
3 in 9. Six samples showed predominant nuclear staining, 30
samples showed predominant cytoplasmic staining, and 45
samples showed both cytoplasmic and nuclear staining (Fig. 7A–
E). In contrast, RAD51 expression was low or absent in normal
tissues surrounding the carcinoma (Fig.7F). However, we found no
correlation between RAD51 expression levels and the clinicopath-
ological parameters in ESCCs (Table 1). Nevertheless, our results
Figure 4. Berberine downregulates RAD51 in tumor cells. (A), The levels of DNA repair proteins in esophageal cancer cells treated with
berberine. Cells were treated with berberine at the indicated concentrations and for the indicated duration before cells were prepared for cell
extracts. (B), Decrease in RAD51 mRNA levels after berberine exposure. Cells were exposed to berberine (15 mM) for 24 h for KYSE30 cells (48 h for
KYSE450 cells), and collected for quantitative real-time PCR analysis of the RAD51/GAPDH mRNA ratios. (C), RAD51 promoter activity was suppressed
by berberine in KYSE30 and KYSE450 cells. The pGL3-RAD51p luciferase (firefly) reporter plasmids were transiently transfected into human
esophageal cancer cells. Four h later, the cells were treated with berberine for 24 h, and then assayed for luciferase activity. Firefly luciferase values
were normalized to Renilla luciferase activity from a co-transfected pRL-SV40 control vector. Each value represents the mean SE for three
independent experiments. Statistical analysis was performed using unpaired Student’s t test. *,P ,0.05 as compared with control values. (D), Lack of
RAD51 downregulation in nonmalignant cells. Cells were exposed to berberine (15 mM) for the specified time period and collected for immunoblot
analysis. (E), Downregulation of RAD51 in other types of cancer cells. Cells were exposed to the designated berberine concentration for 48 h and
collected for immunoblot analysis. The immunoblots shown in A, D, and E are representative of at least two independent experiments with GAPDH
serving as a protein loading control. C indicates cultures exposed to the vehicle control DMSO.
doi:10.1371/journal.pone.0023427.g004
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specimens. Because overexpression of RAD51 usually confers
resistance to agents that damage DNA [29,30,31], our results call
for measures that downregulate RAD51 in order to attain high
radio- or chemotherapeutic efficacy of ESCCs in clinical settings.
Interestingly, berberine treatment also down-regulated RAD51 in
three additional esophageal cancer cell lines (KYSE410, EC109,
and TE-1), as in KYSE30 and KYSE450 cells (data not shown),
suggesting that the berberine may render radiosensitizing effect to
a broad array of esophageal cancer cells.
Discussion
We demonstrated for the first time that berberine can efficiently
downregulate RAD51 expression in cancer cells in conferring
radiosensitivity. Berberine treatment led to a reduction in RAD51
transcription and an inhibition of RAD51 promoter activity. It can
also overcome the upregulation of RAD51 that is induced by
ionizing radiation (IR). The radiosensitizing effect of berberine was
attenuated in cancer cells overexpressing exogenous RAD51.
Downregulation of RAD51, which is essential for homologous
recombination repair, greatly impaired the repair of DSBs induced
by IR and led to poor survival of IR-treated cells. Importantly, we
observed that RAD51 was commonly upregulated in human
ESCC tissues, which may render resistance to therapies that target
DNA. Therefore, administration of berberine as a radio- and
chemosensitizer may serve as a strategy in the treatment of ESCC
patients.
Upregulation of RAD51 in cancer cells was shown to be
associated with increased chemoresistance [29,30]. Several
previous studies also showed that some anti-cancer drugs render
cancer cells radiosensitive and chemosensitive by downregulating
RAD51 and consequently impairing homologous recombination
repair in cancer cells. For example, imatinib (Gleevec), which
inhibits c-Abl tyrosine kinase, can efficiently reduce the expression
of RAD51 in cancer cells and confer radiosensitivity [24,32].
Gefitinib, a selective epidermal growth factor receptor tyrosine
kinase inhibitor, was found to downregulate RAD51 in lung
cancer cells and sensitize them to mitomycin C [33] and
gemcitabine [34]. Phenyl hydroxamic acid PCI-24781, a histone
deacetylase inhibitor that has a radiosensitizing effect on cancer
cells, also acts by downregulating RAD51 [35]. Besides having an
array of side effects, these drugs tend to be very costly.
Many natural products have remarkable medicinal values.
Besides being more affordable, herbal medicines usually have a
low toxicity. Several natural compounds have been found to
confer radiosensitivity and chemosensitivity on cancer cells. One
study showed that curcumin, a component in turmeric (Curcuma
Figure 5. Upregulation of RAD51 by IR can be attenuated by berberine. (A), Radiation enhances RAD51 expression in tumor cells. Cells were
exposed to the indicated doses of radiation and collected 24 h later for immunoblot analysis. (B), Change of RAD51 protein levels in response to
berberine and radiation. Cells were pretreated with berberine (15 mM) for 24 h before being irradiated with 6 Gy of X-rays. Cells were collected for
immunoblot analysis at 24 h after irradiation. (C), Inhibition of radiation-induced RAD51 foci formation by berberine. Shown are immunofluorescence
images of KYSE30 and KYSE450 cells stained with anti-RAD51 antibody after 24 h of pretreatment with berberine and at 24 h after irradiation with
6 Gy of X-rays. DAPI counterstaining showed the nuclei. (D), RAD51 mRNA levels after pretreatment with berberine (15 mM) for 24 h (KYSE30) or 48 h
(KYSE450) before irradiation with 6 Gy. Cells were collected for quantitative real-time PCR analysis of the RAD51/GAPDH mRNA ratios at 24 h after
exposure to 6 Gy of X-rays. Immunoblots and mRNA expression values are representative of at least two independent experiments.
doi:10.1371/journal.pone.0023427.g005
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NFkB function, which led to a downregulation of the anti-
apoptotic gene Bcl-2 [36]. Treatment of cervical cancer cells with
curcumin led to enhanced production of IR-induced reactive
oxygen species (ROS), which causes sustained ERK1/2-MAPK
activation [37]. In contrast, emodin, a substance found in some
plants including rhubarb, was reported to inhibit the activation of
ERK1/2 in lung cancer cells, which in turn leads to a
downregulation of RAD51 and confers chemosensitivity [38,39].
Huang Lian is one of the most commonly used medicinal herbs
in China. It is one of the 12 most commonly used medicinal herbs
in the United States [40]. Besides its common use as a drug for
gastrointestinal discomfort, berberine has been tested in clinical
trials for type 2 diabetes mellitus [41,42] and on hypercholester-
olemia [43]. Importantly, patients taking berberine experience
relatively mild side effects. While previous studies showed that
berberine possesses direct anti-tumor effects by inducing the
production of reactive oxygen species in cancer cells, which would
Figure 7. RAD51 is up-regulated in human esophageal cancer specimens. Images of showing different expression level and cellular
distribution are shown. (A), absence of RAD51-specific staining (blue nuclei due to Mayer’s Hemalum counterstaining). (B), low levels of RAD51 in the
cytoplasm, but not in nuclei, of the invasive carcinoma cells. (C), intermediate levels of RAD51 in both the cytoplasm and nuclei of the invasive
carcinoma cells. (D), high levels of RAD51 in the cytoplasm, but not in nuclei, of the invasive carcinoma cells. (E), high levels of nuclear RAD51 in the
nuclei of invasive carcinoma cells. No cytoplasm staining is evident. (F), absence of RAD51 staining in normal esophageal tissue.
Immunohistochemistry was done as in Materials and Methods. All original images were captured at6400 magnification.
doi:10.1371/journal.pone.0023427.g007
Figure 6. RAD51 expression level determines radiosensitivity of ESCC cells. (A), Downregulation of RAD51 by siRNA. RAD51 protein levels
were measured by Western blot. KYSE30 and KYSE450 cells were transfected with siRNA duplexes (200 nM) specific to RAD51 or negative oligo in
serum-free medium for 4 h, then replaced with complete medium for 24 h. Whole cell extracts were collected for western blot analysis using RAD51
antibodies. (B). Reduced formation of radiation-induced RAD51 foci in esophageal cancer cells in which RAD51 was silenced by RNAi. Cells were
exposed to 6 Gy of X-rays at 28 h following transfection with siRNA duplexes. (C), Effect of RAD51 knockdown on radiosensitivity of esophageal
cancer cells as determined by clonogenic survival assay. (D), Western blot analysis of RAD51 protein in cancer cells that were transfected with
pcDNA3.1 or pcDNA3.1B-mRAD51. The immunoblots shown are representative of two independent experiments with GAPDH serving as a protein
loading control (KYSE30/KYSE450 parent cell line, KYSE30/KYSE450 (pcDNA3.1) cells stably transfected with pcDNA3.1, KYSE30/KYSE450 (mRAD51)
cells stably transfected with pcDNA3.1B-mRAD51). (E), Effect of RAD51 overexpression on radiosensitivity of esophageal cancer cells as determinedb y
clonogenic survival assay. The results for the cells transfected with the mRAD51 or pcDNA3.1 vector treated with berberine were compared
(*P,0.01).
doi:10.1371/journal.pone.0023427.g006
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the first to show that berberine can confer radiosensitivity by
downregulating a key player in the repair of DSBs. It should be
noted that the potency of berberine in downregulating RAD51 in
ESCC cells is comparable to that of Gleevec in glioma cells [24].
At higher concentrations, berberine is expected to play a dual role
in promoting the death of the cells in which it is retained, by
simultaneously inflicting DNA damage and impairing a pathway
that is responsible for the repair of the damage. Importantly, at
concentrations that confer radiosensitivity to esophageal cancer
cells, berberine had no radiosensitizing effect on normal human
fibroblasts. Correspondingly, berberine was not observed to
downregulate RAD51 in nonmalignant cells. These results suggest
that the radiosensitizing effect of berberine may be specific to
cancer cells.
In summary, we showed that berberine at low concentrations
substantially radiosensitized esophageal squamous cell carcinoma
cells. It acts by downregulating RAD51, a key player in
homologous recombination repair, leading to impairment in the
repair of double-strand breaks. Our findings thus uncovered a
hitherto unrecognized biological activity of a commonly used and
inexpensive drug and indicated that berberine, with its relatively
low toxicity, may be used as an adjuvant in cancer radiation
therapy.
Materials and Methods
Ethics Statement
All procedures involving clinical samples were approved by the
Ethics Committee of Shandong University School of Medicine.
Cell Lines
All cells were grown at 37uC in humidified incubator containing
5% CO2. The human esophageal squamous cell carcinoma
(ESCC) lines KYSE30, KYSE450, KYSE410, EC109 and TE-1
were obtained from Cancer Institute & Hospital, Chinese
Academy of Medical Sciences (Beijing) and cultured in RPMI
1640 supplemented with 10% fetal bovine serum, 100 units/mL
penicillin, and 100 mg/mL streptomycin. KYSE30, KYSE450 and
KYSE410 were originally generated by Dr. Yutaka Shimada,
Normal human fibroblast (NHF) cells were obtained from the
Institute of Basic Medical Sciences, Chinese Academy of Medical
Sciences (Beijing), and were maintained in DMEM supplemented
with 10% fetal bovine serum, 100 units/mL penicillin-streptomy-
cin and 4 mg/mL bFGF. HUVECs were obtained from ATCC.
Mesenchymal stem cells derived from human umbilical cord were
a gift from Dr. Dong Li, Qilu Hospital, Shandong University.
Fibroblasts (XWXL) were established from a surgically removed
fibroadenoma, with informed consent of the patient and approved
by Ethics Committee of Shandong University School of Medicine.
The other cell lines used in this study were obtained from the Cell
Bank of Chinese Academy of Sciences (Shanghai).
Chemicals
The chloro-derivative of berberine was from Sigma Chemical
(St Louis, MO). We refer to berberine chloride as berberine
hereinafter. A 50 mM stock solution was prepared in DMSO and
stored at 280uC in aliquots until use. MTT, (3-[4,5-dimethyl-2-
yl]-2,5-diphenyl tetrazolium bromide), and all other chemicals
were of analytical grade and purchased from Sigma Chemical.
MTT assay
Cells in early log phase were trypsinized and plated in 96-well
cell culture plates at the concentration of 225610
3 cells/well.
Twenty-four h later, the medium was removed and replaced with
fresh medium with or without berberine. Cell density was
measured on day 1, 2 and 3 by using the MTT following the
manufacturer’s instructions. The absorbance of converted dye is
measured at the wavelength of 490 nm and the absorbance is
directly proportional to cell viability. For these studies, all
experiments were repeated three or more times.
Clonogenic survival assay
The survival and proliferation potential of cells treated with
berberine and/or ionizing radiation were assessed by clonogenic
assays. Briefly, the cells were treated with the vehicle control
(DMSO) or 15 mM berberine for the indicated time and then
irradiated using a Faxitron Cabinet X-ray System (Faxitron X-ray
Corp., Wheeling, IL) to deliver the indicated doses at room
temperature. The X-rays were filtered through a 0.5 mm
aluminum filter resulting in a dose rate of 0.4 Gy/min. Cells
were trypsinized, suspended in complete medium, counted and
replated in 100-mm tissue culture dishes to allow formation of
macroscopic colonies. Plates were incubated at 37uC for 7 to 14
days, fixed with methanol, stained with Giemsa, and colonies
containing at least 50 cells in size were counted. The fraction
surviving a given x-ray dose was calculated based on the survival of
nonirradiated cells treated with the vehicle or berberine.
Immunofluorescence staining of c-H2AX and Rad51
Cells were grown on coverslips in 6 well plates and treated with
berberine and/or X-ray. At specified times, medium was
aspirated, washed in PBS thrice and cells were fixed in 4%
paraformaldehyde for 15 minutes at room temperature, followed
by treatment with 0.2% Triton X-100 in PBS for 5 minutes. Cells
were then washed in PBS twice and then blocked with 5% bovine
serum albumin in PBS for 30 minutes, following which mouse
anti-c-H2AX antibody (Millipore, Billerica, MA) or rabbit anti-
Rad51 antibody (Santa Cruz, CA) was added at a dilution of 1:600
and 1:300 in 5% bovine serum albumin in PBS respectively and
incubated overnight at 4uC. Cells were then washed thrice in PBS
before incubating in the dark with a Rhodamine-labeled or FITC-
labeled secondary antibody at a dilution of 1:300 in 5% bovine
serum albumin in PBS for 60 minutes. The secondary antibody
solution was then aspirated and the cells were washed four times in
Table 1. Lack of association between RAD51 levels and the
clinicopathological parameters in ESCC specimens.
Characteristic Category N=86 (%)
RAD51
012 3
P-
value
Gender
Age (years)
Tumor
differentiation
Depth of invasion
Tumor size (cm)
Lymph node
status
Stage
Male
Female
$60
,60
Well
Moderate
Poor
T1-T2
T3-T4
$5
,5
negative
positive
Low (I and II)
High (III and IV)
73(81.4%)
13(18.6%)
45(52.3%)
41(47.7%)
16(18.6%)
39(45.3%)
30(36.1%)
23(26.7%)
63(73.3%)
23(26.7%)
63(73.3%)
39(45.4%)
47(54.6%)
10(11.6%)
76(88.4%)
42 6 3 5 8
13 8 1
4 1 81 85
11 1 2 5 4
15 9 1
2 9 24 4
21 5 1 0 4
19 1 2 1
42 0 3 18
29 1 0 2
32 0 3 37
21 2 2 23
31 7 2 16
06 4 0
52 3 3 99
0.406
0.199
0.446
0.306
0.306
0.306
0.306
doi:10.1371/journal.pone.0023427.t001
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phenylindole (1 mg/mL) in PBS for 5 minutes and coverslips were
mounted with an antifade solution (Molecular Probes, Eugene,
OR). Slides were then examined on a Leica fluorescent
microscope. Images were captured by a charge coupled device
camera. For each treatment condition, c-H2AX foci were counted
in at least 100 cells from randomly captured images.
Western Blot Analysis
Cells were harvested after treatment with berberine and/or X-
ray, rinsed in ice-cold PBS, and lysed in lysis buffer containing
50 mmol/L HEPES (pH 7.9), 0.4 mol/L NaCl, 1 mmol/L
EDTA, 2 mg/mL leupeptin, 2 mg/mL aprotinin, 5 mg/mL
benzamidine, 0.5 mmol/L phenylmethylsulfonylfluoride, and 1%
NP40. The lysates were centrifuged at 12,000 rpm to remove any
cellular debris. Protein concentrations of the lysates were
determined by the BCA protein assay system (Beyotime, China).
Equal amounts of protein were separated by 10% SDS-PAGE,
transferred to PVDF membrane (Millipore, Billerica, MA), and
blocked with 5% nonfat dry milk in TBS-Tween 20 (0.1%, v/v) for
1 hour at room temperature. The membrane was incubated with
primary antibody overnight. Antibodies to Ku70, Ku86, and
RAD51 were from Santa Cruz Biotechnology (Santa Cruz, CA);
and GAPDH was from Chemicon (Temecula, CA). After washing,
the membrane was incubated with the appropriate horseradish
peroxidase secondary antibody (diluted 1:5,000; Amersham
Pharmacia Biotech, Arlington Heights, IL) for 1 hour. Following
several washes, the blots were developed by enhanced chemilu-
minescence (Millipore, Billerica, MA).
cDNA synthesis and real-time PCR
RNA was isolated using TRIzol reagent (Invitrogen) according
to the manufacturer’s protocol. cDNA was synthesized by reverse
transcription of 1 mg of total RNA with random hexamers. The
total volume of reverse transcription reaction was 20 ml. Real-time
quantitative reverse transcription-PCR was performed using the
ABI Prism 7500 sequence Detection System (Applied Biosystems,
Inc., Foster City, CA). Human GAPDH gene was used as an
internal control. The levels of RAD51 and GAPDH mRNA were
measured by SYBR Green I assay. RAD51 was amplified by using
the primers with the sequence 59-CAACCCATTTCACGGTTA-
GAGC-39 (forward) and 59-GCTTTGGCTTCACTAATTCCC
TT-39(reverse) in conjunction with thermal cycling program
consisting of one cycle for 2 min at 50uC and for 10 min at
95uC, and 40 cycles for 15 s at 95uC and for 1 min at 60uC. 26
cycles of 95uC for 30 s, 61uC for 30 s and 72uC for 60 s.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was am-
plified as an internal control. The GAPDH primer was 59-
CAGAACATCATCCCTGCCTCTAC-39 (forward) and 59-
TTGAAGTCAGAGGAGACCACCTG-39 (reverse). The sam-
ples were loaded in quadruple, and the results of each sample were
normalized to GAPDH.
Luciferase reporter assay
The sequence of promoter and 59end of RAD51 (from 21693 to
+487 bp of the transcriptions start site-numbered according to
Entrez Gene ID 5888, gi:19924132) was cloned into pGL3-basic
vector. Primers are available upon request. For transfection,
5610
5 KYSE30 and KYSE450 cells were seeded in duplicate into
6-well culture plates and transfected with 1 mg of reporter
construct using lipofectamine 2000 (Invitrogen) per the manufac-
turer’s instructions. Cells were incubated with/without berberine
(15 mM) for 24 h then harvested. Firefly and Renilla luciferase
activities were measured by using the Dual-Luciferase Reporter
Assay System kit (Promega) and assessed with a luminometer.
Renilla luciferase activity from a cotransfected pRL-SV40 control
vector (50 ng/well) was used for normalization.
RAD51 depletion by RNA interference
RAD51 siRNA duplex 1, 2 and 3 and the negative oligo were
obtained from GenePharma (Shanghai, China). siRNA duplexes
or negative oligo (200 nM) were transfected into KYSE30 and
KYSE450 cells using lipofectamine2000 (Invitrogen) for 24 h.
RAD51 protein levels were determined by western blotting
analysis and the levels of radiosensitivity were determined by
clonogenic assay described above.
Sequences for small interfering RNA for RAD51 RNAi are as
follows:
siRAD51-1: CGAUGUGAAGAAAUUGGAATT
siRAD51-2: GACUGGAUCUAUCACAGAATT
siRAD51-3: GCAGUGAUGUCCUGGAUAATT
Expression vector of mRAD51
Plasmid pcDNA3.1B-mRAD51 was constructed by PCR-ampli-
fying the cDNA of mRAD51 from the pCMV-SPORT6- mRAD51
cDNA plasmid (Open Biosystems, Huntsville, AL) with primers:
GCGGGATCCACTATGGCTATGCAAATGCAGCTTGAAG
and TATCTCGAGCGGTCTTTGGCATCGCCCACTCCATC
TG. After a double cut with BamH I and Xho I, the PCR product
was inserted into a pcDNA3.1/myc-His B vector (Invitrogen,
Carlsbad, CA, USA) that was opened by the same restriction
enzymes. The mRAD51 insert was verified by sequencing.
Immunohistochemistry
ESCC specimens were from the collection in the Department
of Pathology, Qilu Hospital. The use of the specimens was
approved the Ethics Committee of Shandong University School
of Medicine. Immunohistochemical staining was performed using
the PV6000 IHC Kit (Zhongshan Goldenbridge Biotechnology
Co. Ltd., China). Briefly, paraffin sections (4 mm) of human
ESCC samples were heated, dewaxed, and hydrated in xylene
and ethanol/H2O. Antigen was retrieved by microwave oven
heating (10 min) at middle power in 0.01 mol/L sodium citrate
buffer (pH 6.0). The sections were then incubated in 3%
hydrogen peroxide in absolute methanol at room temperature
for 10 min, to block endogenous peroxidase activity. After three
rinses (each for 5 min) in PBS, the sections were incubated with
rabbit anti-human RAD51 antibody (1:75, SCBT, Santa Cruz,
CA), diluted in PBS overnight at 4uC, with 150 ml polymerized
HRP-anti mouse/rabbit IgG for 30 min at room temperature.
The reaction products were visualized with diaminobenzidine
(DAB Kit; Zhongshan Goldenbridge Biotechnology), and slides
were counterstained with hematoxylin, dehydrated, and evaluat-
ed under light microscope. Negative controls were done by
omitting primary antibodies. The intensity of staining within the
nucleus and the cytoplasm of the cells was assessed. A sample was
classified as positive if more than 10% of the cells (malignant or
benign) were stained with the RAD51 antibody with intensity
greater than 0. A consensus score of expression intensity (1, low;
2, moderate; and 3, strong) was reached by two investigators (Q.
Liu, C. Hao) for each sample.
Statistical Analysis
For each measurement, three or four independent experiments
were performed. Results were expressed as mean 6 SEM.
Statistical calculations were performed using the SigmaPlot 2000
software (Systat Software, San Jose, CA). Differences in measured
Berberine Downregulates RAD51 in Cancer Cells
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using t-test. P,0.05 was considered statistically significant.
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